| Bioactivity | Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1]. | ||||||||||||
| Invitro | Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted[1]. | ||||||||||||
| In Vivo | Repaglinide (AG-EE 623ZW) is very rapidly absorbed (tmax less than 1 hour) with a t1/2 of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective (P<0.001) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes. | ||||||||||||
| Name | Repaglinide | ||||||||||||
| CAS | 135062-02-1 | ||||||||||||
| Formula | C27H36N2O4 | ||||||||||||
| Molar Mass | 452.59 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore). 2018 Sep;97(38):e12476. |